ArticleACS omega2026
Optimization of 3D Spheroid Models of Ovarian, Breast, and Gastric Cancer for Comparative Screening of Drug Candidates.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three-dimensional (3D) spheroid models are increasingly used in cancer research because they reproduce several features of solid tumors that are not represented in conventional two-dimensional (2D) monolayer cultures. In the present study, we developed and optimized spheroid culture conditions for a panel of breast, ovarian, and gastric cancer cell lines grown on low-attachment plates. Spheroid formation, morphology, and growth behavior were assessed during culture, and the resulting models were used for the comparative testing of reference anticancer agents. The established assay framework was further applied to newly developed cyclin-dependent kinase 7 (CDK7) inhibitor candidates from our in-house compound library. Anticancer activity was evaluated by using AlamarBlue or PrestoBlue viability assays after prolonged drug exposure. Reproducible spheroid formation conditions were identified for the studied cell lines, although notable cell line-specific differences in morphology, growth behavior, and assay duration were observed. Comparative drug testing revealed differences in apparent sensitivity between 2D and 3D cultures depending on the cell line and compound. Several tested CDK7 inhibitor candidates reduced viability in the spheroid models, with iCDK7_1 showing the strongest activity across the evaluated panel. Overall, the study describes and applies a cell line-adapted 3D spheroid assay workflow for comparative evaluation of antiproliferative effects in breast, ovarian, and gastric cancer models.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.